P723 Therapeutic thresholds for golimumab serum concentrations during induction and maintenance: Results from the GO-LEVEL study
ECCO'20 Vienna
2020
P724 Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels
ECCO'20 Vienna
2020
P725 Trends in biologic use prior to resective surgery for inflammatory bowel disease: A Canadian population-based study
ECCO'20 Vienna
2020
P726 Effectiveness of vedolizumab therapy in a real-world setting in Germany: First results of the VEDOibd study comparing vedolizumab to the use of other biologics
ECCO'20 Vienna
2020
P727 Small bowel capsule endoscopy impact on therapeutic decisions in established Crohn’s disease: Analysis of a real-world data
ECCO'20 Vienna
2020
P729 The SAPPHIRE registry: Safety of immunosuppression in a prospective cohort of inflammatory bowel disease patients with a HIstoRy of CancEr
ECCO'20 Vienna
2020
P730 Effectiveness and safety of endoscopic balloon dilation of colorectal strictures in Crohn’s disease
ECCO'20 Vienna
2020
P731 Biologics use in elderly patients with IBD: Experience in a UK secondary care setting
ECCO'20 Vienna
2020
P733 The influence of concomitant familial Mediterranean fewer on Crohn’s disease course: Data from an FMF endemic area
ECCO'20 Vienna
2020
P734 Should we have a higher threshold for anti-TNF serum levels in Crohn’s disease patients with perianal disease?
ECCO'20 Vienna
2020
P735 Comparative assessment of probiotics and standard therapies for mild to moderate ulcerative colitis: A systematic review and network meta-analysis
ECCO'20 Vienna
2020
P736 Utility of infliximab serum concentration in inflammatory bowel disease treatment in real world practice at Hospital Universitario de Canarias
ECCO'20 Vienna
2020
P737 Ustekinumab induction effectiveness in Crohn’s disease in a real-life cohort
ECCO'20 Vienna
2020
P738 Real world outcomes on the efficacy and safety of combination of biologic and immunosuppressive therapy in liver transplant recipients with inflammatory bowel disease
ECCO'20 Vienna
2020
P739 Patients with Crohn’s disease with intestinal failure have less active disease than patients with Crohn’s disease without intestinal failure
ECCO'20 Vienna
2020